These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 28530521)

  • 1. The Direct Cost of Managing a Rare Disease: Assessing Medical and Pharmacy Costs Associated with Duchenne Muscular Dystrophy in the United States.
    Thayer S; Bell C; McDonald CM
    J Manag Care Spec Pharm; 2017 Jun; 23(6):633-641. PubMed ID: 28530521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
    Buono JL; Mathur K; Averitt AJ; Andrae DA
    J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterizing demographics, comorbidities, and costs of care among populations with Duchenne muscular dystrophy with Medicaid and commercial coverage.
    Klimchak AC; Szabo SM; Qian C; Popoff E; Iannaccone S; Gooch KL
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1426-1437. PubMed ID: 34595954
    [No Abstract]   [Full Text] [Related]  

  • 4. Development and electronic health record validation of an algorithm for identifying patients with Duchenne muscular dystrophy in US administrative claims.
    Schrader R; Posner N; Dorling P; Senerchia C; Chen Y; Beaverson K; Seare J; Garnier N; Walker V; Alvir J; Mahn M; Merla V; Zhang Y; Landis C; Buikema AR
    J Manag Care Spec Pharm; 2023 Sep; 29(9):1033-1044. PubMed ID: 37610111
    [No Abstract]   [Full Text] [Related]  

  • 5. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
    J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare resource utilization and cost among patients with type 1 diabetes in the United States.
    Simeone JC; Shah S; Ganz ML; Sullivan S; Koralova A; LeGrand J; Bushman J
    J Manag Care Spec Pharm; 2020 Nov; 26(11):1399-1410. PubMed ID: 33119443
    [No Abstract]   [Full Text] [Related]  

  • 8. Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting.
    Chastek B; Korrer S; Nagar SP; Albers F; Yancey S; Ortega H; Forshag M; Dalal AA
    J Manag Care Spec Pharm; 2016 Jul; 22(7):848-61. PubMed ID: 27348285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with Idiopathic Membranous Nephropathy: A Real-World Clinical and Economic Analysis of U.S. Claims Data.
    Nazareth TA; Kariburyo F; Kirkemo A; Xie L; Pavlova-Wolf A; Bartels-Peculis L; Vaidya N; Sim JJ
    J Manag Care Spec Pharm; 2019 Sep; 25(9):1011-1020. PubMed ID: 31283419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States.
    Thornburg CD; Adamski K; Cook K; Vembusubramanian M; Sendhil SR; Hinds D; Chen E; Sammon J; Solari P; Garrison LP; Croteau SE
    J Manag Care Spec Pharm; 2022 Apr; 28(4):449-460. PubMed ID: 34958235
    [No Abstract]   [Full Text] [Related]  

  • 11. Health care utilization and costs for children and adults with duchenne muscular dystrophy.
    Teoh LJ; Geelhoed EA; Bayley K; Leonard H; Laing NG
    Muscle Nerve; 2016 Jun; 53(6):877-84. PubMed ID: 26562484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States.
    Lu M; Oladapo A; Wu Y; Farahbakhshian S; Ewenstein B
    J Manag Care Spec Pharm; 2021 Feb; 27(2):175-185. PubMed ID: 33307935
    [No Abstract]   [Full Text] [Related]  

  • 13. Association between health system specialty pharmacy use and health care costs among national sample of Medicare Advantage beneficiaries.
    Hellems SS; Soni A; Fasching D; Smith BS; McManus DD
    J Manag Care Spec Pharm; 2022 Feb; 28(2):244-254. PubMed ID: 35098745
    [No Abstract]   [Full Text] [Related]  

  • 14. Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis.
    Croteau SE; Cook K; Sheikh L; Chawla A; Sammon J; Solari P; Kim B; Hinds D; Thornburg CD
    J Manag Care Spec Pharm; 2021 Mar; 27(3):316-326. PubMed ID: 33645244
    [No Abstract]   [Full Text] [Related]  

  • 15. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
    Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
    J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study.
    Reaven NL; Funk SE; Montouris GD; Saurer TB; Story TJ
    Epilepsy Behav; 2018 Nov; 88():66-73. PubMed ID: 30241056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of Patients Receiving Novel Muscular Dystrophy Drugs in Trials vs Routine Care.
    Hong D; Avorn J; Wyss R; Kesselheim AS
    JAMA Netw Open; 2024 Jan; 7(1):e2353094. PubMed ID: 38265797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Assessment of Medical Resource Use and Costs Associated with Patients with Symptomatic Peripheral Artery Disease in the United States.
    Chase MR; Friedman HS; Navaratnam P; Heithoff K; Simpson RJ
    J Manag Care Spec Pharm; 2016 Jun; 22(6):667-75. PubMed ID: 27231794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct Costs of Opioid Abuse in an Insured Population in the United States.
    White AG; Birnbaum HG; Mareva MN; Daher M; Vallow S; Schein J; Katz N
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1188-1198. PubMed ID: 32996392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe.
    Cavazza M; Kodra Y; Armeni P; De Santis M; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Taruscio D; Schieppati A; Iskrov G; Péntek M; von der Schulenburg JM; Kanavos P; Chevreul K; Persson U; Fattore G;
    Eur J Health Econ; 2016 Apr; 17 Suppl 1():19-29. PubMed ID: 27038625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.